Arcutis Begins Phase 3 Enrollment for ZORYVE Atopic Dermatitis Study
The INTEGUMENT-3 study will evaluate ZORYVE (roflumilast) cream 0.3% in moderate to severe atopic dermatitis.
The INTEGUMENT-3 study will evaluate ZORYVE (roflumilast) cream 0.3% in moderate to severe atopic dermatitis.